https://www.selleckchem.com/pr....oducts/tiplaxtinin-p
IAL REGISTRATION ClinicalTrials.gov no. NCT02824159.INTRODUCTION Migraine is a debilitating neurological disease and one of the most common disorders in the world. Although the triptans, potent 5-HT1B/1D receptor agonists, are an effective and widely used acute treatment of migraine, few studies have assessed how their cardiovascular risk warnings could impact prescription patterns. This study characterized cardiovascular risk factors and other aspects of people with migraine in real-world settings and confirmed patterns of
Like
Comment
Share
